-

Autobahn Therapeutics to Present at the Stifel 2023 Virtual CNS Days

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced that Kevin Finney, chief executive officer, and Gudarz Davar, M.D., chief medical officer, will present a company overview at the Stifel 2023 Virtual CNS Days on Tuesday, March 28, 2023 at 3:30 p.m. ET.

A live webcast of the presentation can be accessed online here and a replay will be available for 90 days following the presentation.

About Autobahn Therapeutics

Autobahn Therapeutics is focused on restoring hope for people affected by CNS disorders. Leveraging its proprietary brain-targeting chemistry platform, Autobahn aims to unlock new therapeutic opportunities through precision tuning of the central exposure of its molecules. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta agonist, being developed as a potential adjunctive treatment for people with MDD, including those who have had an inadequate response to their antidepressant. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.

Contacts

Alicia Davis, THRUST Strategic Communications
alicia@thrustsc.com

Industry:

Autobahn Therapeutics

Release Versions
English

Contacts

Alicia Davis, THRUST Strategic Communications
alicia@thrustsc.com

More News From Autobahn Therapeutics

Autobahn Therapeutics Reports AMPLIFY-BD Results for Elunetirom in Bipolar Depression, Highlighting Rapid, Robust, and Sustained Improvements in Depressive Symptoms and Functioning

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that full results from its Phase 2 AMPLIFY-BD trial were presented at Psych Congress 2026, which took place September 15-19 in New Orleans, Louisiana. Elunetirom, a novel, oral, once daily, brain-penetrant CNS thyroid hormone receptor agonist, achieved clinically meaningful benefit and statistical significance acros...

Autobahn Therapeutics Reports New Nonclinical Data Showing Elunetirom Rapidly Builds Synaptic Connections and Restores Cellular Energy Capacity in Neurons

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today reported new nonclinical data on the antidepressant mechanism of action for elunetirom, its lead investigational therapy in Phase 2 development for adjunctive treatment of bipolar depression and major depressive disorder (MDD). The data show that elunetirom rapidly increased the number of synaptic connections between neurons...

Autobahn Therapeutics Reports Positive Phase 2 Topline Data for Elunetirom in Bipolar Depression, Demonstrating Rapid, Robust, and Durable Antidepressant Effects

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced positive topline data from its Phase 2 AMPLIFY-BD trial evaluating elunetirom as an adjunctive treatment in patients with bipolar I or bipolar II depression, a disorder affecting approximately 7 million adults in the U.S. Elunetirom, a novel, oral, once daily, brain-penetrant CNS thyroid hormone receptor agonist, ac...
Back to Newsroom